Bahl & Gaynor Inc. Sells 7,046 Shares of Pfizer Inc. (NYSE:PFE)

Bahl & Gaynor Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 8.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,945 shares of the biopharmaceutical company’s stock after selling 7,046 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Pfizer were worth $2,080,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Advisor OS LLC increased its stake in shares of Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC increased its stake in Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares in the last quarter. Lantz Financial LLC boosted its holdings in shares of Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after buying an additional 381 shares during the last quarter. Wellington Shields Capital Management LLC boosted its holdings in shares of Pfizer by 1.3% in the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 385 shares during the last quarter. Finally, King Wealth Management Group boosted its holdings in shares of Pfizer by 2.4% in the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 388 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PFE shares. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Barclays lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 10th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, July 10th. Finally, Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $34.50.

Pfizer Trading Down 0.4 %

Shares of Pfizer stock traded down $0.12 during trading on Tuesday, reaching $29.48. 13,251,520 shares of the stock were exchanged, compared to its average volume of 39,724,246. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $28.43 and its 200 day moving average is $27.73. The firm has a market cap of $167.05 billion, a price-to-earnings ratio of -491.08, a price-to-earnings-growth ratio of 1.17 and a beta of 0.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the business posted $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.70%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.